Completed OBSERVATIONAL NCT04521465

Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

A Multi-Center, Single Arm, Post-Market Clinical Follow-up Study to Evaluate the Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

Sponsor: Novaliq GmbH

Conditions Evaporative Dry Eye Disease

Interventions NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)

Updated 7 times since 2020 Last updated: Apr 14, 2021 Started: Nov 9, 2020 Primary completion: Feb 17, 2021 Completion: Feb 17, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Evaporative Dry Eye Disease and is currently completed. Novaliq GmbH leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2021 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Feb 2021 — May 2021 [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novaliq GmbH

Data source: Novaliq GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany
• Nuremberg, Germany